Cable Hill Partners LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,180 shares of the company’s stock after selling 378 shares during the period. Johnson & Johnson accounts for about 0.4% of Cable Hill Partners LLC’s holdings, making the stock its 21st biggest position. Cable Hill Partners LLC’s holdings in Johnson & Johnson were worth $1,975,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Glassy Mountain Advisors Inc. purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $35,000. Retirement Financial Solutions LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $40,000. TD Capital Management LLC bought a new stake in Johnson & Johnson during the third quarter valued at approximately $48,000. VitalStone Financial LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC lifted its position in Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Up 0.3 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. Johnson & Johnson’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.67 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.93%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is currently 94.56%.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on JNJ shares. UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price for the company. StockNews.com began coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a report on Friday. SVB Leerink lowered their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Finally, Raymond James decreased their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $173.00.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
- An Opportunity To Buy Starbucks Is Knocking On The Door
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
